AU2001293473A1 - Diphosphonate solutions - Google Patents

Diphosphonate solutions

Info

Publication number: AU2001293473A1
Authority: AU; Australia
Prior art keywords: solution; pharmaceutical product; product according; glass; polymer
Prior art date: 2000-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001293473A

Other languages

English (en)

Inventor

Gregory Paul Handreck

Russell John Tait

Wei Zhou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mayne Pharma International Pty Ltd

Original Assignee

FH Faulding and Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-18

Filing date

2001-09-18

Publication date

2002-03-26

2000-09-18 Priority claimed from AUPR0189A external-priority patent/AUPR018900A0/en

2001-05-10 Priority claimed from AUPR4855A external-priority patent/AUPR485501A0/en

2001-09-18 Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd

2001-09-18 Priority to AU2001293473A priority Critical patent/AU2001293473A1/en

2002-03-26 Publication of AU2001293473A1 publication Critical patent/AU2001293473A1/en

2006-08-03 Assigned to MAYNE PHARMA INTERNATIONAL PTY LTD reassignment MAYNE PHARMA INTERNATIONAL PTY LTD Request for Assignment Assignors: F.H. FAULDING & CO. LIMITED

Status Abandoned legal-status Critical Current

Links

XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 title claims description 20
239000000243 solution Substances 0.000 claims description 82
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 63
239000011521 glass Substances 0.000 claims description 33
239000000825 pharmaceutical preparation Substances 0.000 claims description 32
229940127557 pharmaceutical product Drugs 0.000 claims description 32
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 22
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 20
238000000034 method Methods 0.000 claims description 18
229920000642 polymer Polymers 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 11
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
229930195725 Mannitol Natural products 0.000 claims description 10
239000000594 mannitol Substances 0.000 claims description 10
235000010355 mannitol Nutrition 0.000 claims description 10
229940046231 pamidronate Drugs 0.000 claims description 8
238000002386 leaching Methods 0.000 claims description 7
150000007524 organic acids Chemical class 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical group FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 claims description 6
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
239000007853 buffer solution Substances 0.000 claims description 6
-1 chlodronate Chemical compound 0.000 claims description 6
229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 claims description 6
239000012535 impurity Substances 0.000 claims description 6
239000011347 resin Substances 0.000 claims description 6
229920005989 resin Polymers 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 6
239000000463 material Substances 0.000 claims description 5
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 4
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical group FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 4
229920002620 polyvinyl fluoride Polymers 0.000 claims description 4
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims description 4
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 3
230000004888 barrier function Effects 0.000 claims description 3
229910052681 coesite Inorganic materials 0.000 claims description 3
229910052906 cristobalite Inorganic materials 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
229910052682 stishovite Inorganic materials 0.000 claims description 3
229910052905 tridymite Inorganic materials 0.000 claims description 3
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 3
229960004276 zoledronic acid Drugs 0.000 claims description 3
229920001774 Perfluoroether Polymers 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
239000004743 Polypropylene Substances 0.000 claims description 2
229940062527 alendronate Drugs 0.000 claims description 2
238000005137 deposition process Methods 0.000 claims description 2
229940009626 etidronate Drugs 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
229920000306 polymethylpentene Polymers 0.000 claims description 2
239000011116 polymethylpentene Substances 0.000 claims description 2
229920001155 polypropylene Polymers 0.000 claims description 2
229920001296 polysiloxane Polymers 0.000 claims description 2
229940019375 tiludronate Drugs 0.000 claims description 2
239000002002 slurry Substances 0.000 claims 1
238000005406 washing Methods 0.000 claims 1
239000004411 aluminium Substances 0.000 description 11
229910052782 aluminium Inorganic materials 0.000 description 11
229960003978 pamidronic acid Drugs 0.000 description 11
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
239000011575 calcium Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000002156 mixing Methods 0.000 description 7
239000008215 water for injection Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
229910021645 metal ion Inorganic materials 0.000 description 5
229910052710 silicon Inorganic materials 0.000 description 5
239000010703 silicon Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000012905 visible particle Substances 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000011109 contamination Methods 0.000 description 3
229910001873 dinitrogen Inorganic materials 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000003076 Osteolysis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229960004343 alendronic acid Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000002956 ash Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
PFBUKDPBVNJDEW-UHFFFAOYSA-N dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940025708 injectable product Drugs 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960005324 tiludronic acid Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Detergent Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

AU2001293473A 2000-09-18 2001-09-18 Diphosphonate solutions Abandoned AU2001293473A1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2001293473A AU2001293473A1 (en)	2000-09-18	2001-09-18	Diphosphonate solutions

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
AUPR0189		2000-09-18
AUPR0189A AUPR018900A0 (en)	2000-09-18	2000-09-18	Pamidronate solution
AUPR4855A AUPR485501A0 (en)	2001-05-10	2001-05-10	Stable injectable solutions
AUPR4855		2001-05-10
AU2001293473A AU2001293473A1 (en)	2000-09-18	2001-09-18	Diphosphonate solutions
PCT/AU2001/001171 WO2002022136A1 (en)	2000-09-18	2001-09-18	Diphosphonate solutions

Publications (1)

Publication Number	Publication Date
AU2001293473A1 true AU2001293473A1 (en)	2002-03-26

Family

ID=25646444

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001293473A Abandoned AU2001293473A1 (en)	2000-09-18	2001-09-18	Diphosphonate solutions

Country Status (10)

Country	Link
US (3)	US20040082545A1 (pl)
EP (2)	EP1318818A4 (pl)
KR (1)	KR20030043931A (pl)
CN (1)	CN1441674A (pl)
AU (1)	AU2001293473A1 (pl)
CA (1)	CA2406446A1 (pl)
NO (1)	NO20031215L (pl)
PL (1)	PL360910A1 (pl)
TW (1)	TW200418494A (pl)
WO (1)	WO2002022136A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY141763A (en) *	2003-09-18	2010-06-30	Novartis Ag	Pharmaceutical products comprising bisphosphonates
WO2006100687A1 (en) *	2005-03-24	2006-09-28	Dabur Pharma Ltd.	Disodium pamidronate aqueous formulation
US7605148B2 (en) *	2007-04-16	2009-10-20	Aurobindo Pharma Ltd.	Aqueous oral solution of bisphosphonic acid
EP2363111A1 (en) *	2010-03-01	2011-09-07	Combino Pharm, S.L.	Stable pharmaceutical composition comprising bisphosphonate
AR075721A1 (es) *	2010-03-05	2011-04-20	Eriochem Sa	Composicion farmaceutica que comprende una solucion de acido zoledronico.
WO2011127629A1 (zh) *	2010-04-16	2011-10-20	台湾东洋药品工业股份有限公司	双磷酸注射液医药产品及其制法
CN116077446A (zh) *	2022-12-16	2023-05-09	上药东英（江苏）药业有限公司	一种雷贝拉唑钠冻干粉针剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7612534L (sv) *	1975-12-01	1977-06-02	Henkel & Cie Gmbh	Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
US4304734A (en) *	1980-10-16	1981-12-08	Vysoka Skola Chemicko-Technologicka	6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4639338A (en) *	1984-08-06	1987-01-27	Ciba-Geigy Corporation	Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US5219556A (en) *	1990-07-09	1993-06-15	Mallinckrodt Medical, Inc.	Stabilized therapeutic radiopharmaceutical complexes
US5167816A (en) *	1990-08-20	1992-12-01	Abbott Laboratories	Sterile coupling device for drug container
DE4228552A1 (de) *	1992-08-27	1994-03-03	Boehringer Mannheim Gmbh	Diphosphonsäuren und deren Salze enthaltende Arzneimittel
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations
JP3672342B2 (ja) *	1994-09-26	2005-07-20	アステラス製薬株式会社	ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル
US5853894A (en) *	1997-02-03	1998-12-29	Cytonix Corporation	Laboratory vessel having hydrophobic coating and process for manufacturing same
US6087350A (en) *	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6174873B1 (en) *	1998-11-04	2001-01-16	Supergen, Inc.	Oral administration of adenosine analogs
US6794536B1 (en) *	1998-12-10	2004-09-21	Aesqen, Inc.	Method for preparation of disodium pamidronate
US6160165A (en) *	1998-12-10	2000-12-12	Aesgen, Inc.	Method for preparation of disodium pamidronate
CA2353942A1 (en) *	1998-12-10	2000-06-15	Edward C. Shinal	Method for preparation of disodium pamidronate
US6309596B1 (en) *	1998-12-15	2001-10-30	Bausch & Lomb Incorporated	Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine
US6167369A (en) *	1998-12-23	2000-12-26	Xerox Company	Automatic language identification using both N-gram and word information
BR0009200A (pt) *	1999-03-22	2001-12-26	Immugen Pharmaceuticals Inc	Compostos e composições para o tratamento dedoenças associada com disfunção imune
US6211169B1 (en) *	1999-09-29	2001-04-03	Aesgen, Inc.	Stable calcitriol solution for packaging into vials
EP1136069A1 (en) *	2000-03-21	2001-09-26	SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A.	Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration
DE20106394U1 (de) *	2001-04-11	2001-08-09	Helm Pharmaceuticals Gmbh	Pharmazeutische Zubereitung
EP1390044A4 (en) *	2001-05-02	2005-03-23	Sicor Inc	PAMIDRONATE DINATRIUM FOR INJECTION

2001
- 2001-09-18 AU AU2001293473A patent/AU2001293473A1/en not_active Abandoned
- 2001-09-18 EP EP01973807A patent/EP1318818A4/en not_active Withdrawn
- 2001-09-18 PL PL36091001A patent/PL360910A1/pl not_active Application Discontinuation
- 2001-09-18 CN CN01812743A patent/CN1441674A/zh active Pending
- 2001-09-18 CA CA002406446A patent/CA2406446A1/en not_active Abandoned
- 2001-09-18 US US10/380,645 patent/US20040082545A1/en not_active Abandoned
- 2001-09-18 KR KR10-2003-7002186A patent/KR20030043931A/ko not_active Ceased
- 2001-09-18 EP EP06007027A patent/EP1671638A1/en not_active Withdrawn
- 2001-09-18 WO PCT/AU2001/001171 patent/WO2002022136A1/en not_active Ceased
- 2001-09-19 TW TW093111927A patent/TW200418494A/zh unknown
2003
- 2003-03-17 NO NO20031215A patent/NO20031215L/no not_active Application Discontinuation
2005
- 2005-07-26 US US11/190,493 patent/US20060154900A1/en not_active Abandoned
- 2005-07-28 US US11/194,106 patent/US20060154898A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20031215D0 (no)	2003-03-17
CA2406446A1 (en)	2002-03-21
EP1318818A1 (en)	2003-06-18
WO2002022136A1 (en)	2002-03-21
US20060154900A1 (en)	2006-07-13
KR20030043931A (ko)	2003-06-02
EP1671638A1 (en)	2006-06-21
US20060154898A1 (en)	2006-07-13
CN1441674A (zh)	2003-09-10
TW200418494A (en)	2004-10-01
PL360910A1 (pl)	2004-09-20
US20040082545A1 (en)	2004-04-29
EP1318818A4 (en)	2004-09-29
NO20031215L (no)	2003-05-16

Legal Events

Date	Code	Title	Description
2007-07-26	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

Publication	Publication Date	Title
AU2004271731B2 (en)	2008-07-24	Pharmaceutical products comprising bisphosphonates
US20120027818A1 (en)	2012-02-02	Bisphosphonate product in a cycloolefinic polymer container
US20040082545A1 (en)	2004-04-29	Diphosphonate solutions
JP3118258B2 (ja)	2000-12-18	ジホスホン酸およびその塩を含有する医薬品
EP1216057B1 (en)	2003-11-12	Stable calcitriol solution for packaging in vials
US20130040915A1 (en)	2013-02-14	Pharmaceutical composition
AU2021200491A1 (en)	2021-02-25	Diphosphonate solutions
US20030138462A1 (en)	2003-07-24	Pamidronate solution
AU2014218411A1 (en)	2014-09-18	Diphosphonate solutions
AU2010227060A1 (en)	2010-11-04	Diphosphonate solutions
US20050182030A1 (en)	2005-08-18	Liquid injectable formulation of disodium pamidronate
HK1055907A (en)	2004-01-30	Diphosphonate solutions
KR20120121403A (ko)	2012-11-05	디포스포네이트 주사액 의약품 및 그 제법
US20060217350A1 (en)	2006-09-28	Disodium pamidronate formulation
MXPA06003126A (en)	2007-04-10	Pharmaceutical products comprising bisphosphonates